Accelerate Diagnostics Announces Proposed Public Offering of Common Stock, No Terms Disclosed

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (“Accelerate Diagnostics”) today announced that it has commenced an underwritten public offering of shares of its common stock. Accelerate Diagnostics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less the underwriting discounts and commissions. Accelerate Diagnostics anticipates using the net proceeds from the offering for general corporate purposes and to fund commercialization efforts. All of the shares are being offered by Accelerate Diagnostics. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.